Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway

Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway

Alopecia areata (AA) is an immune-mediated condition, clinically manifesting as non-cicatricial patches of alopecia. It is often a self-limiting condition; however, regrowth of hair can take a long period of time, resulting in significant psychological comorbidity. With the recent advances in pathom...

Full description

Bibliographic Details
Main Authors: Kabir Sardana, Savitha Bathula, Ananta Khurana
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Indian Dermatology Online Journal
Subjects:
alopecia areata
baricitinib
cyclosporine
deucravacitinib
hair cycling
ifidancitinib
ifn-γ
il-15
jak inhibitors
jak/stat
methotrexate
ritlecitinib
tofacitinib
Online Access:http://www.idoj.in/article.asp?issn=2229-5178;year=2023;volume=14;issue=4;spage=465;epage=474;aulast=Sardana

Internet

http://www.idoj.in/article.asp?issn=2229-5178;year=2023;volume=14;issue=4;spage=465;epage=474;aulast=Sardana

Similar Items